GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » Institutional Ownership

Arovella Therapeutics (FRA:E4NA) Institutional Ownership : 0.32% (As of Jun. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arovella Therapeutics's institutional ownership is 0.32%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arovella Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arovella Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.


Arovella Therapeutics Institutional Ownership Historical Data

The historical data trend for Arovella Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Institutional Ownership Chart

Arovella Therapeutics Historical Data

The historical data trend for Arovella Therapeutics can be seen below:

2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 0.48 0.47 0.36 0.36 0.32 0.32

Arovella Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Arovella Therapeutics (FRA:E4NA) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton, WA, AUS, 3053
Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics (FRA:E4NA) Headlines

No Headlines